An Open Label, Single Arm, Extension Study to Evaluate the Long Term Safety and Sustained Efficacy of Denosumab (AMG162) in the Treatment of Postmenopausal Osteoporosis
Latest Information Update: 30 Jan 2023
At a glance
- Drugs Denosumab (Primary)
- Indications Postmenopausal osteoporosis; Vertebral fracture
- Focus Adverse reactions
- Acronyms FREEDOM extension
- Sponsors Amgen
- 01 May 2022 Results published in the Journal of Bone and Mineral Research
- 26 Mar 2022 Results of retrospective analysis appling updated built in tissue thickness-adjusted TBS algorithm to investigate the long-term effect of denosumab on bone microarchitecture in FREEDOM and OLE in patients who completed the FREEDOM DXA substudy , presented at the 2022 World Congress on Osteoporosis, Osteoarthritis and Musculoskeletal Diseases
- 19 Nov 2020 Results of post hoc analysis evaluating the long-term safety and efficacy of denosumab in subjects with mild-to-moderate CKD published in the Journal of Clinical Endocrinology and Metabolism